Published Studies Related to Protonix Injection (Pantoprazole)
Well-designed clinical trials related to Protonix Injection (Pantoprazole)
Randomized placebo-controlled trial of pantoprazole for daytime sleepiness in GERD and obstructive sleep disordered breathing. [2008.08]
A pilot study of efficacy and safety of continuous intravenous infusion of pantoprazole in the treatment of severe erosive esophagitis. [2008.06]
Intermittent intravenous pantoprazole and continuous cimetidine infusion: effect on gastric pH control in critically ill patients at risk of developing stress-related mucosal disease. [2008.05]
Comparative tolerability of 2- and 15-minute intravenous infusions of pantoprazole. [2007.09.01]
Prospective, randomized trial comparing effect of oral versus intravenous pantoprazole on rebleeding after nonvariceal upper gastrointestinal bleeding: a pilot study. [2007.09]
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. [2007.09]
A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving 'complete remission' in gastro-oesophageal reflux disease. [2007.06.15]
High-dose pantoprazole continuous infusion is superior to somatostatin after endoscopic hemostasis in patients with peptic ulcer bleeding. [2007.06]
Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial - the EMANCIPATE study. [2007.03]
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. [2007.02.15]
Effect of intravenous application of esomeprazole 40 mg versus pantoprazole 40 mg on 24-hour intragastric pH in healthy adults. [2007.02]
Oral rabeprazole vs. intravenous pantoprazole: a comparison of the effect on intragastric pH in healthy subjects. [2007.01.15]
Pantoprazole 40 mg is as effective as esomeprazole 40 mg to relieve symptoms of gastroesophageal reflux disease after 4 weeks of treatment and superior regarding the prevention of symptomatic relapse. [2007]
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. [2007]
Pantoprazole on-demand effectively treats symptoms in patients with gastro-oesophageal reflux disease. [2007]
Bioequivalence of two enteric coated formulations of pantoprazole in healthy volunteers under fasting and fed conditions. [2007]
Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. [2006.10.07]
Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). [2006.10]
Continuous infusion of pantoprazole versus ranitidine for prevention of ulcer rebleeding: a U.S. multicenter randomized, double-blind study. [2006.09]
Effects of 3-day IV pantoprazole versus omeprazole on 24-hour intragastric acidity at 3 days in Chinese patients with duodenal ulcer: A single-center, prospective, randomized, comparative, pilot trial. [2006.09]
Esomeprazole versus pantoprazole for healing erosive oesophagitis. [2006.09]
Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. [2006.09]
Intravenous pantoprazole as initial treatment in patients with gastroesophageal reflux disease and a history of erosive esophagitis: a randomized clinical trial. [2006.09]
Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. [2006.08]
Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers. [2006.05]
Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole. [2006.04.15]
Pantoprazole infusion as adjuvant therapy to endoscopic treatment in patients with peptic ulcer bleeding: prospective randomized controlled trial. [2006.04]
Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. [2006.04]
Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults. [2006.01]
Pantoprazole 40 mg Is as Effective as Esomeprazole 40 mg to Relieve Symptoms of Gastroesophageal Reflux Disease after 4 Weeks of Treatment and Superior regarding the Prevention of Symptomatic Relapse. [2006]
Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. [2005.11.01]
A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. [2005.11]
Pantoprazole 20 mg on demand is effective in the long-term management of patients with mild gastro-oesophageal reflux disease. [2005.09]
Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals. [2005.07]
Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. [2005.06.15]
Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial. [2005.05]
Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine. [2005.01]
On-demand therapy with pantoprazole 20 mg as effective long-term management of reflux disease in patients with mild GERD: the ORION trial. [2005]
Novel measurement of rapid treatment success with ReQuest: first and sustained symptom relief as outcome parameters in patients with endoscopy-negative GERD receiving 20 mg pantoprazole or 20 mg esomeprazole. [2005]
Intravenous pantoprazole versus ranitidine for prevention of rebleeding after endoscopic hemostasis of bleeding peptic ulcers. [2004.12.15]
Recent success of pantoprazole -or lansoprazole- based clarithromycin plus amoxicillin treatment in the eradication of Helicobacter pylori. [2004.12]
The effect of intravenous pantoprazole and ranitidine for improving preoperative gastric fluid properties in adults undergoing elective surgery. [2003.11]
Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously. [2001.07]
Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. [1998.10]
Pantoprazole lacks interaction with antipyrine in man, either by inhibition or induction. [1996.05]
Pantoprazole does not interact with nifedipine in man under steady-state conditions. [1996.05]
Well-designed clinical trials possibly related to Protonix Injection (Pantoprazole)
Effect of CYP2C19*2 and *17 mutations on pharmacodynamics and kinetics of proton pump inhibitors in Caucasians. [2008.05]
Role of sequential therapy in Helicobacter pylori eradication therapy. [2007.10]
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. [2007.04.17]
Evaluation of pantoprazol treatment response of patients with asthma and gastroesophageal reflux: a randomized prospective double-blind placebo-controlled study. [2007.04]
Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. [2007.01.15]
Does Adding Misoprostol to Standard Intravenous Proton Pump Inhibitor Protocol Improve the Outcome of Aspirin/NSAID-Induced Upper Gastrointestinal Bleeding? : A Randomized Prospective Study. [2007.01]
Acetylsalicylic acid as an adjuvant therapy for schizophrenia. [2006.10.23]
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. [2006.10]
Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs. [2006.09.01]
[Financial restrictions in health care systems could affect treatment quality of GERD-patients] [2006.05]
Lansoprazole regimens that sustain intragastric pH > 6.0: an evaluation of intermittent oral and continuous intravenous infusion dosages. [2006.04.01]
Proton pump inhibition prevents gastrointestinal bleeding in ultramarathon runners: a randomised, double blinded, placebo controlled study. [2006.04]
What is the best way to manage GERD symptoms in the elderly? [2006.03]
Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. [2006]
Review article: prevention of stress-related mucosal bleeding with proton-pump inhibitors. [2005.12]
Other research related to Protonix Injection (Pantoprazole)
Intermittent versus Continuous Pantoprazole Infusion in Peptic Ulcer Bleeding: A Prospective Randomized Study. [2008.09.29]
Effect of Preoperative Intravenous Pantoprazole in Elective-Surgery Patients: A Pilot Study. [2008.08.27]
Efficacy and safety of pantoprazole 20 mg once daily treatment in patients with ulcer-like functional dyspepsia. [2008.07]
Intravenous pantoprazole utilization in a level 1 trauma center. [2008.04]
Pantoprazole: from drug metabolism to clinical relevance. [2008.04]
Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation. [2008.03]
Comparative bioavailability study with two pantoprazole delayed-released tablet formulations administered with and without food in healthy subjects. [2008]
Effect of increasing esomeprazole and pantoprazole doses on Acid control in patients with symptoms of gastro-oesophageal reflux disease : a randomized, dose-response study. [2008]
Bioequivalence study of two enteric-coated formulations of pantoprazole in healthy volunteers under fed conditions. [2008]
A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection. [2007.12]
A Pilot Study of Efficacy and Safety of Continuous Intravenous Infusion of Pantoprazole in the Treatment of Severe Erosive Esophagitis. [2007.11.06]
Comparison of 1- and 2-week pantoprazole-based triple therapies in clarithromycin-sensitive and resistant cases. [2007.10]
RANDOMIZED TRIAL COMPARING PANTOPRAZOLE INFUSION, BOLUS AND NO TREATMENT ON GASTRIC pH AND RECURRENT BLEEDING IN PEPTIC ULCERS. [2007.08]
Low-dose intravenous pantoprazole for optimal inhibition of gastric acid in Korean patients. [2007.07.20]
Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. [2007.07.15]
Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: evaluation of mechanisms. [2007.07.03]
Effect of intravenous esomeprazole 40 mg and pantoprazole 40 mg on intragastric pH in healthy subjects. A prospective, open, randomised, two-way cross-over comparative study. [2007]
The concept of complete remission of gastro-oesophageal reflux disease : comparative efficacy of pantoprazole and esomeprazole using the ReQuest questionnaire. [2007]
Effect of pantoprazole in older patients with erosive esophagitis. [2007]
Long-term management of GERD in the elderly with pantoprazole. [2007]
Inappropriate use of intravenous pantoprazole: extent of the problem and successful solutions. [2005.12]
Intragastric pH during continuous infusion with pantoprazole in patients with bleeding peptic ulcer. [2003.12]
[Visual documentation of the stability of intravenous solutions of omeprazole (Losec) and pantoprazole (Pantoloc)] [2002]
Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. [2001.12]
Switching between intravenous and oral pantoprazole. [2001.01]
Clinical experience with pantoprazole in gastroesophageal reflux disease. [2000.10]
Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. [2000.04]
Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian Intravenous Pantoprazole Study Group. [1999.05]
Pharmacokinetics of pantoprazole in man. [1996.05]
Effect of pantoprazole on 24-h intragastric pH and serum gastrin in humans. [1994]
Other possibly related research studies
Pre-endoscopic proton pump inhibitor therapy reduces recurrent adverse gastrointestinal outcomes in patients with acute non-variceal upper gastrointestinal bleeding. [2006.10.15]
Intravenous proton pump inhibitors. [2006.01]
Intravenous proton pump inhibitor therapy: a rationale for use. [2005]
Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study. [2005.11]
Use of intravenous proton pump inhibitors in community practice: an explanation for the shortage? [2004.07]
Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding. [2003.03]
Intravenous proton pump inhibitors in the critical care setting. [2002.06]
Optimizing the intragastric pH as a supportive therapy in upper GI bleeding. [1996.05]
Pharmacokinetics--a relevant factor for the choice of a drug? [1994]
Single intravenous administration of the H+, K(+)-ATPase inhibitor BY 1023/SK&F 96022--inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. [1990.06]
|
